NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Monday it plans to offer $100 million in convertible senior notes due 2017.

Proceeds from the private offering will be used to continue commercialization of its MaterniT21 Plus LDT non-invasive aneuploidy test and for general corporate purposes, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.